Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 69

of 'Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia'

Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients.
Valeyrie L, Bastuji-Garin S, Revuz J, Bachot N, Wechsler J, Berthaud P, Tulliez M, Giraudier S
J Am Acad Dermatol. 2003;48(2):201.
BACKGROUND: Imatinib is a new major treatment in chronic myeloid leukemia.
OBJECTIVE: To study the cutaneous reactions induced by imatinib.
METHODS: All inpatients and outpatients with Philadelphia chromosome-positive leukemia treated by imatinib were included in this prospective study. Clinical features, pathologic findings, evolution of each case, and analysis of potential risk factors were recorded.
RESULTS: A total of 54 patients were included, 48 of whom experienced at least 1 cutaneous reaction. These reactions consisted of 36 rashes, 35 edemas, and 22 pruritus. The rash was severe in 5 patients, resulting in temporary interruption of treatment in 3. Highly significant relationships were observed between the daily dose of imatinib and both rashes and edema. In a multivariate analysis, female sex and the daily dose of imatinib were independent risk factorsfor the development of rashes.
CONCLUSION: Adverse cutaneous reactions induced by imatinib are frequent, generally moderate, and dose-dependent.
Department of Dermatology, Henri-Mondor Hospital (Assistance Publique Hopitaux de Paris), Paris XII University, F-94010 Paris Cedex, France.